New drug cocktail aims to improve remission in older leukemia patients
NCT ID NCT02494882
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This phase I trial tests the safety of adding ruxolitinib to a standard combination of dasatinib and dexamethasone for adults aged 40 and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study starts with a low dose of ruxolitinib and gradually increases it to find the safest dose. All three drugs have been used before in humans, but this is the first time they are combined for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib, Dasatinib, Dexamethasone
- What this could lead to
- If this combination proves safe, it could lead to a more effective remission induction therapy for older adults with Ph+ ALL.
- What could go wrong
- This is a small, early-phase safety study, so the combination may not work better than standard treatments and could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diet and exercise program help childhood leukemia survivors live healthier?
- Could bone marrow from deceased donors cure blood cancers?
- Double-Pronged immune cells take aim at stubborn blood cancers
- Lab-Grown stem cells could speed immune recovery in blood cancer transplants
- Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission
- Radioactive antibody hones in on cancer cells to boost transplant success